What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?

被引：18
|
作者：
Liu, Joyce F. [1 ]
Matulonis, Ursula A. [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA
来源：
CURRENT ONCOLOGY REPORTS | 2016年 / 18卷 / 05期
关键词：
Ovarian cancer; PARP inhibitors; Olaparib; Veliparib; Rucaparib; Niraparib; RECURRENT EPITHELIAL OVARIAN; OLAPARIB MAINTENANCE THERAPY; RECOMBINATION DNA-REPAIR; NEGATIVE BREAST-CANCER; HOMOLOGOUS RECOMBINATION; POLY(ADP-RIBOSE) POLYMERASE; FALLOPIAN-TUBE; DOWN-REGULATION; PHASE-II; PRIMARY PERITONEAL;
D O I：
10.1007/s11912-016-0515-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Poly-ADP-ribose polymerase (PARP) inhibitors have been one of the most exciting developments in the treatment of ovarian cancer in recent years. Demonstration of anticancer activity has led to the European Medicines Agency (EMA) approval of the PARP inhibitor (PARPi) olaparib as maintenance therapy in women with BRCA-mutated (BRCAm) ovarian cancer with platinum-sensitive recurrence following response to platinum therapy and the US Food and Drug Administration (US FDA) approval of olaparib in relapsed germline BRCA-mutated (gBRCAm) ovarian cancer in women who have received at least three prior chemotherapy treatments, both occurring in 2014. Additional trials are underway or awaiting final analysis with olaparib, other PARPis, and PARPi combinations to further elucidate the activity of these drugs in various clinical settings. This review will focus on the current clinical experience and ongoing trials with PARPis in ovarian cancer.
引用
收藏
页数：9
相关论文
共 50 条
  • [21] PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies
    Bahena-Gonzalez, Antonio
    Toledo-Leyva, Alfredo
    Gallardo-Rincon, Dolores
    [J]. CHINESE CLINICAL ONCOLOGY, 2020, 9 (04)
  • [22] Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
    Tang, Bin
    Wu, Min
    Zhang, Lin
    Jian, Shuyi
    Lv, Shiyi
    Lin, Tongyuan
    Zhu, Shuangshuang
    Liu, Layang
    Wang, Yixue
    Yi, Zhengfang
    Jiang, Feiyun
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [23] The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
    Gien, Lilian T.
    Mackay, Helen J.
    [J]. JOURNAL OF ONCOLOGY, 2010, 2010
  • [24] PARP INHIBITORS IN OVARIAN CANCER THERAPY
    Pisula, Agata
    Sienicka, Agnieszka
    Dobrowolska-Redo, Agnieszka
    Kacperczyk-Bartnik, Joanna
    Romejko-Wolniewicz, Ewa
    [J]. PROSPECTS IN PHARMACEUTICAL SCIENCES, 2024, 22 (02): : 71 - 74
  • [25] PARP Inhibitors in Ovarian Cancer: A Review
    David M. O’Malley
    Thomas C. Krivak
    Nashwa Kabil
    Jiefen Munley
    Kathleen N. Moore
    [J]. Targeted Oncology, 2023, 18 : 471 - 503
  • [26] PARP Inhibitors in Ovarian Cancer Reply
    Ray-Coquard, Isabelle
    Perol, David
    Pujade-Lauraine, Eric
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (16): : 1574 - 1575
  • [27] PARP inhibitors in ovarian cancer FOREWORD
    Cibula, David
    Balmana, Judith
    [J]. BRITISH JOURNAL OF CANCER, 2015, 113 : S1 - S2
  • [28] PARP Inhibitors in Breast and Ovarian Cancer
    Wang, Samuel S. Y.
    Jie, Yeo Ee
    Cheng, Sim Wey
    Ling, Goh Liuh
    Ming, Heong Valerie Yue
    [J]. CANCERS, 2023, 15 (08)
  • [29] The Maze of PARP Inhibitors in Ovarian Cancer
    Nair, Abhilasha
    Chen, Alice P.
    Pothuri, Bhavana
    [J]. ONCOLOGY-NEW YORK, 2012, 26 (02): : 136 - +
  • [30] PARP inhibitors in the ovarian cancer therapy
    Kruczala, Maksymilian A.
    Grela-Wojewoda, Aleksandra
    Cedrych, Ida
    [J]. GINEKOLOGIA POLSKA, 2016, 87 (02) : 131 - 134
12345